Home World News FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative...

FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

September 9, 2026

140

Evidence for efficacy is based on the results from the Study 1 of the VIKTORIA-1